complement factor H related 3Genealiases: CFHL3 · DOWN16 · FHR-3 · FHR3 · HLF4
Q-omics provides the consensus-scored CFHR3 profile across patient tissues and cancer cell-line models. CFHR3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CFHR3 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CFHR3 protein abundance shows 31,666 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where CFHR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFHR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFHR3 survival associations across molecular data types. CFHR3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFHR3 RNA expression–survival associations across cancer types. High CFHR3 expression shows unfavorable associations in KIRC, CHOL, LGG, COAD and KIRP, but favorable associations in LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CFHR3 RNA expression.
This table summarizes CFHR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 12. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CFHR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFHR3 shows lower tumor expression in KICH, LIHC and BRCA and higher tumor expression in HNSC, LUAD and LUSC. The HNSC box plot shows higher CFHR3 RNA expression in tumor versus normal tissue (log2 FC = +0.403, t-test p < 0.001).
This table shows molecular features associated with CFHR3 in patient tissues and cancer cell lines. In patient samples, CFHR3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CFHR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
